Filtered By:
Condition: Diabetes
Drug: Metformin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3129 results found since Jan 2013.
Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma
Endocrinology. 2023 Sep 20:bqad139. doi: 10.1210/endocr/bqad139. Online ahead of print.ABSTRACTOral squamous cell carcinoma (OSCC) is one of the most common malignancies with high mortality, posing a great threat to both human physical and mental health. With the advancement of scientific research, a variety of cancer therapies have been used for OSCC treatment. However, the prognosis of OSCC shows no significant improvement. Metformin has been recognized as the first-line drug for the treatment of diabetes, and recent studies have shown that metformin has a remarkable suppressive effect on tumor progression. Metformin can...
Source: Endocrinology - September 22, 2023 Category: Endocrinology Authors: Jiayi Liu Jing Zhao Xue Qiao Source Type: research
New insights on the potential anti-epileptic effect of metformin: Mechanistic pathway
In conclusion, metformin might be an adjuvant with AEAs in the management of refractory epilepsy. Preclinical and clinical studies are warranted in this regard.PMID:37737447 | DOI:10.1111/jcmm.17965
Source: Molecular Medicine - September 22, 2023 Category: Molecular Biology Authors: Saud A Alnaaim Hayder M Al-Kuraishy Ali I Al-Gareeb Naif H Ali Athanasios Alexiou Marios Papadakis Hebatallah M Saad Gaber El-Saber Batiha Source Type: research
Gestational Diabetes Mellitus: Update on Screening, Diagnosis, and Management
Am Fam Physician. 2023 Sep;108(3):249-258.ABSTRACTGestational diabetes mellitus (GDM) is a common condition of pregnancy with increasing prevalence in the United States. GDM increases risks of complications, including operative delivery, hypertensive disorders, shoulder dystocia, fetal macrosomia, large-for-gestational-age infants, neonatal hypoglycemia, and neonatal respiratory distress. In patients who are overweight or obese, prepregnancy weight loss and lifestyle modifications during pregnancy may prevent GDM. First-trimester screening can identify preexisting diabetes and early-onset GDM for prompt implementation of g...
Source: American Family Physician - September 19, 2023 Category: Primary Care Authors: Joshua S Will Holly Crellin Source Type: research
Bioderived cellulose fibre-guar gum grafted poly (N, N'-dimethylacrylamide) polymer network for controlled release of metformin hydrochloride
Int J Biol Macromol. 2023 Sep 15:126882. doi: 10.1016/j.ijbiomac.2023.126882. Online ahead of print.ABSTRACTAn interpenetrating polymer network (IPN) of areca cellulose and guar gum grafted with poly (N, N'-dimethylacrylamide) was made by microwave irradiation technique. N, N-methylenebisacrylamide (MBA) was used as the crosslinking agent. The network polymer was characterised using Fourier Transform Infrared Spectroscopy (FTIR), Thermogravimetric Analysis (TGA), Powder X-ray Diffraction (XRD) and Field Emission Scanning Electron Microscopy (FESEM). The chemical interaction between the drug and the polymer was studied usin...
Source: International Journal of Biological Macromolecules - September 17, 2023 Category: Biochemistry Authors: Smitha Rai Ruchira Raychaudhuri Ritu Kudarha Srinivas Mutalik B Vishalakshi K M Usha Source Type: research
Metformin and Covid-19: a systematic review of systematic reviews with meta-analysis
Conclusions More in-depth studies on the use of metformin, compared to other molecules, may be required to understand the real protective potential of the drug against negative outcomes caused by COVID-19 infection in DM2 patients.PMID:37695186 | DOI:10.23750/abm.v94iS3.14405
Source: Acta Bio-Medica : Atenei Parmensis - September 11, 2023 Category: General Medicine Authors: Fabio Petrelli Iolanda Grappasonni Cuc Thi Thu Nguyen Marina Tesauro Paola Pantanetti Sonila Xhafa Giovanni Cangelosi Source Type: research
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
J Clin Oncol. 2023 Sep 11:JCO2300296. doi: 10.1200/JCO.23.00296. Online ahead of print.ABSTRACTClinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Metformin has been associated with lower cancer risk in epidemiologic and preclinical research. In the MA.32 rando...
Source: Clinical Breast Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Pamela J Goodwin Bingshu E Chen Karen A Gelmon Timothy J Whelan Marguerite Ennis Julie Lemieux Jennifer A Ligibel Dawn L Hershman Ingrid A Mayer Timothy J Hobday Judith M Bliss Priya Rastogi Manuela Rabaglio-Poretti Alastair M Thompson Daniel W Rea Paul M Source Type: research
Metformin and Covid-19: a systematic review of systematic reviews with meta-analysis
Conclusions More in-depth studies on the use of metformin, compared to other molecules, may be required to understand the real protective potential of the drug against negative outcomes caused by COVID-19 infection in DM2 patients.PMID:37695186 | DOI:10.23750/abm.v94iS3.14405
Source: Acta Bio-Medica : Atenei Parmensis - September 11, 2023 Category: General Medicine Authors: Fabio Petrelli Iolanda Grappasonni Cuc Thi Thu Nguyen Marina Tesauro Paola Pantanetti Sonila Xhafa Giovanni Cangelosi Source Type: research
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
J Clin Oncol. 2023 Sep 11:JCO2300296. doi: 10.1200/JCO.23.00296. Online ahead of print.ABSTRACTClinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Metformin has been associated with lower cancer risk in epidemiologic and preclinical research. In the MA.32 rando...
Source: Clinical Genitourinary Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Pamela J Goodwin Bingshu E Chen Karen A Gelmon Timothy J Whelan Marguerite Ennis Julie Lemieux Jennifer A Ligibel Dawn L Hershman Ingrid A Mayer Timothy J Hobday Judith M Bliss Priya Rastogi Manuela Rabaglio-Poretti Alastair M Thompson Daniel W Rea Paul M Source Type: research
Metformin and Covid-19: a systematic review of systematic reviews with meta-analysis
Conclusions More in-depth studies on the use of metformin, compared to other molecules, may be required to understand the real protective potential of the drug against negative outcomes caused by COVID-19 infection in DM2 patients.PMID:37695186 | DOI:10.23750/abm.v94iS3.14405
Source: Acta Bio-Medica : Atenei Parmensis - September 11, 2023 Category: General Medicine Authors: Fabio Petrelli Iolanda Grappasonni Cuc Thi Thu Nguyen Marina Tesauro Paola Pantanetti Sonila Xhafa Giovanni Cangelosi Source Type: research
